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Abstract
Tumor growth is caused by the acquisition of driver mutations, which enhance the
net reproductive rate of cells. Driver mutations may increase cell division, reduce
cell death,or allow cells toovercome density-limiting effects. We studythe dynam-
ics of tumor growth as one additional driver mutation is acquired. Our models are
based on two-type branching processes that terminate in either tumor disappear-
ance or tumor detection. In our ﬁrst model, both cell types grow exponentially,
withafasterrateforcells carryingtheadditional driver.We ﬁndthatthe additional
driver mutation does not affect the survival probability of the lesion, but can sub-
stantially reduce the time to reach the detectable size if the lesion is slow growing.
In our second model, cells lacking the additional driver cannot exceed a ﬁxed car-
rying capacity, due to density limitations. In this case, the time to detection
depends strongly on this carrying capacity. Our model provides a quantitative
framework for studying tumor dynamics during different stages of progression.
We observe that early, small lesions need additional drivers, while late stage metas-
tases are only marginally affected by them. These results help to explain why addi-
tional driver mutations aretypically not detected in fast-growing metastases.
Introduction
Disease progression in cancer is driven by somatic evolu-
tion of cells (Nordling 1953; Nowell 1976; Vogelstein and
Kinzler 1993; Hanahan and Weinberg 2000; Vogelstein and
Kinzler 2004; Merlo et al. 2006; Gatenby and Gillies 2008).
Mathematical modeling (Wodarz and Komarova 2005) can
provide quantitative insights into many aspects of this pro-
cess, including the age incidence of cancer (Armitage and
Doll 1954; Knudson 1971, 2001; Luebeck and Moolgavkar
2002; Michor et al. 2006; Meza et al. 2008), the role of
genetic instability in tumor progression (Nowak et al.
2002; Komarova et al. 2002, 2003; Michor et al. 2003; Raj-
agopalan et al. 2003; Michor et al. 2005b; Nowak et al.
2006), the timing of disease progression events (Moolgav-
kar and Knudson 1981; Nowak et al. 2003; Iwasa et al.
2004, 2005; Beerenwinkel et al. 2007; Jones et al. 2008a;
Attolini et al. 2010; Bozic et al. 2010; Durrett and Moseley
2010; Gerstung and Beerenwinkel 2010; Yachida et al.
2010; Durrett and Mayberry 2011; Gerstung et al. 2011;
Martens et al. 2011), the evolution of resistance to chemo-
therapy (Coldman and Goldie 1985, 1986; Goldie and
Coldman 1986, 1998), the dynamics of targeted cancer
therapy (Michor et al. 2005a; Dingli and Michor 2006; Le-
der et al. 2011; Bozic et al. 2012; Diaz et al. 2012), and
genetic heterogeneity within tumors (Durrett et al. 2011;
Iwasa and Michor 2011).
Tumors are initiated by a genetic event that provides a
previously normal cell with an increased reproductive rate
(a ﬁtness advantage) compared with surrounding cells. In
the case of colon cancer, this initiating event (usually inac-
tivation of the APC tumor suppressor gene) starts the
growth of a micro-adenoma (Kinzler and Vogelstein 1996).
Subsequent genetic alterations can further increase the
reproductive potential of tumor cells and lead to the devel-
opment of a large adenoma and carcinoma (Vogelstein
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Evolutionary Applicationset al. 1988; Baker et al. 1989; Fearon and Vogelstein 1990).
Metastasis, the dissemination and growth of tumor cells in
distant organs, is thought to occur late in the course of
tumor evolution (Yachida et al. 2010). Few, if any, selective
events are required to transform a highly invasive cancer
cell into one with the capacity to metastasize (Jones et al.
2008a).
Here, we study how one additional driver mutation
affects tumor growth. We model a stochastically growing
lesion and explore the consequence of an additional driver
mutation, which might appear. Driver mutations are
deﬁned as those that increase the ﬁtness of tumor cells and
contribute to the carcinogenic process (Frank and Nowak
2004; Maley et al. 2004; Sjo ¨blom et al. 2006; Greenman
et al. 2007; Wood et al. 2007; Jones et al. 2008b; Parsons
et al. 2008). In cancer biology, the ﬁtness of a cell repre-
sents its reproductive potential. Many different mecha-
nisms can increase the net growth rate of cancerous cells
such as sustaining proliferative signaling, evading growth
suppressors, resisting cell death, or gaining unlimited repli-
cative potential (Hanahan and Weinberg 2011). Driver
mutations constitute only a fraction of the genetic altera-
tions found in tumor cells; the remainder are ‘passengers’,
which do not alter ﬁtness but hitchhike to high frequency
on the basis of driver mutations. Bozic et al. (2010) give a
formula for the predicted relationship between the num-
bers of driver and passenger mutations acquired over time.
We model tumor growth using a discrete-time branching
process (also known as the Galton–Watson process) (Ath-
reya and Ney 1972). We consider two types of cells: resi-
dent (type 0) and mutant (type 1) cells. Mutant cells have
one additional driver mutation with respect to resident
cells. Thus, our model could be thought of as a one-bit
description of tumor dynamics, where one bit encodes the
genotype of a cell with respect to the additional driver
mutation. This model is a generalization of the Luria-Del-
bru ¨ck model used in studying bacterial evolution (Luria
and Delbru ¨ck 1943; Zheng 1999; Dewanji et al. 2005). Sim-
ilar two-type stochastic models of cancer evolution were
previously used to study the evolution of resistance to can-
cer therapy (Goldie and Coldman 1979; Coldman and Gol-
die 1983; Komarova and Wodarz 2005; Iwasa et al. 2006;
Foo and Michor 2010; Bozic et al. 2012; Diaz et al. 2012)
and stochastic dynamics in healthy and preneoplastic tissue
(Clayton et al. 2007; Klein et al. 2010; Antal and Krapivsky
2011).
Our model can be applied to different stages of tumor
progression. For example, the additional driver mutation
could be the mutation activating the KRAS/BRAF pathway
in a small colorectal adenoma, associated with the transfor-
mation from small to large adenoma, or the mutation that
transforms benign adenoma into inﬁltrating carcinoma
(Jones et al. 2008a). Finally, the additional driver mutation
can be a new driver in a metastatic lesion. We are particu-
larly interested in the following question: under which con-
ditions does an additional driver mutation accelerate
tumor progression?
Materials and methods
The model
We model tumor evolution as a discrete-time, two-type
branching process. At each time step, each cell either
divides (yielding two daughter cells) or dies. These events
occur independently for each cell. Each resident cell divides
with probability 1
2ð1 þ s0Þ and dies with probability
1
2ð1   s0Þ. Here, s0 denotes the growth coefﬁcient (which
we deﬁne as division probability minus death probability
per time step) of resident cells, and may be constant or var-
iable depending on the model under consideration (see
below). Similarly, mutant cells divide with probability
1
2ð1 þ s1Þ and die with probability 1
2ð1   s1Þ. When a resi-
Figure 1 Illustration of the branching process. A tumor is initiated with a single resident cell. At each time step, each cell either divides or dies, lead-
ing to a stochastically growing tumor. Resident cells (blue) have a division probability of 1
2ð1 þ s0Þ, while mutant cells (red) have a division probability
of 1
2ð1 þ s1Þ. Additionally, resident cells may mutate upon division, with probability u.
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an additional driver mutation (making it a mutant) with
probability u (Fig. 1). This parameter u reﬂects both the
point mutation rate in resident cells and the number of
positions in the genome that can give rise to the next driver
mutation. Each time step in our model corresponds to the
time between divisions of a typical tumor cell. We assume
that the time between cell divisions is the same for resident
and mutant cells. Tumor progression is initiated by a single
resident cell. We study the dynamics of tumor progression
by considering two possible endpoints: (i) extinction of the
tumor and (ii) the tumor reaches a certain size, M (which
might correspond to clinical detection).
We study two related models that differ in the growth
dynamics of the resident cells.
In the exponential growth model, the growth coefﬁcients
s0 and s1 are constant, so that both resident and mutant
cells grow exponentially on average. Moreover, mutant cells
have a growth advantage compared with resident cells
(s1 [ s0 [ 0) and can therefore potentially accelerate
tumor progression. This model can be viewed as a special
case of the model used in Bozic et al. 2010, in which multi-
ple driver mutations can occur in sequence.
In the logistic growth model, resident cells are con-
strained by a density limit. They grow exponentially at
ﬁrst, but eventually reach a steady state around a certain
number of cells (the carrying capacity K). For our sto-
chastic model, this means that the division probability of
the resident cells varies with tumor size. We achieve this
by considering a variable growth coefﬁcient
~ s0 ¼ s0 ð1   X=KÞ, where X is the current size of the
tumor. In this case, the constant s0 [ 0 represents only
the initial growth coefﬁcient of resident cells (when
X K), while the variable ~ s0 represents the growth coefﬁ-
cient at any tumor size X. For tumor sizes X for which
division probability of resident cells would fall below 0
(or for which, equivalently, ~ s0 would fall below  1), we
set ~ s0 ¼  1. Mutant cells have no density limit, but
rather have a constant growth coefﬁcient s1 [ 0. This
logistic growth model describes the situation where addi-
tional mutations are needed for the tumor to overcome
current geometric and metabolic constraints (Spratt et al.
1993; Jiang et al. 2005). Density-dependent branching
process models have previously been used by Tan (1986)
to model tumor growth and Bozic et al. (2012) to model
acquired resistance to targeted therapy.
(A) (B)
(C) (D)
Figure 2 Driver mutation effect on tumor progression under various conditions. These plots show typical simulation results for the exponential
growth model (A and B) and the logistic growth model (C and D). A higher growth coefﬁcient of the mutant type (s1 ¼ 0:008 in A vs s1 ¼ 0:016 in
B) increases its survival probability and reduces the time until the mutant type becomes dominant. In C and D, the additional driver mutation is neutral
(s1 ¼ s0). The resident cells decline at the point when the mutant cells (and hence the total number of cells) exceed the carrying capacity of the resi-
dent cells. In C, we have aKu > 1; thus, the mutant type arises while the resident type is still expanding (see “Logistic growth model” subsection of
Results). In D, we have aKu < 1 and hence the resident population remains at carrying capacity for a signiﬁcant period of time before the mutant type
arises. Parameter values: driver mutation rate u ¼ 10 6, average cell division time is 3 days.
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We use computer simulations to understand the evolution-
ary dynamics of our stochastic model of tumor progres-
sion. To ensure an efﬁcient processing of the discrete-time
Galton–Watson branching process, we only store the num-
ber of resident and mutant cells in each time step. By sam-
pling from a multinomial distribution, we obtain the
number of cells of both types in the next generation (Bozic
et al. 2010). Note that in the logistic growth model, the
birth probabilities for the resident cells depend on the size
of the tumor, and therefore, we need to calculate them in
each generation.
In Fig. 2 A and B, we show two realizations of the
exponential growth model, corresponding to tumor evo-
lution in two ‘patients’. Similarly, in Fig. 2 C and D, we
show two examples of tumor evolution in the logistic
growth model.
Parameter selection
The effects of additional driver mutations depend on the
driver mutation rate. This rate is the product of the num-
ber of positions in the genome that would lead to a new
driver mutation if altered and the point mutation rate. The
point mutation rate in normal and cancer tissues has been
reported to be in the range 10 11 to 10 9 (Albertini et al.
1990; Cervantes et al. 2002; Jones et al. 2008a). It was esti-
mated that there are  30 000 positions in the genome that
could become driver mutations (Bozic et al. 2010). If any
of them could become the next driver in the tumor, then
the driver mutation rate u would be on the order of
 10 7 to  10 5, and if only a subset of all driver muta-
tions could become the next driver, the driver mutation
rate would be much smaller. Some types of genetic instabil-
ity could additionally increase the point mutation rate
(Thibodeau et al. 1993; Loeb 1994; Lengauer et al. 1998).
To account for all these possibilities, we will consider driver
mutation rates in the range 10 9 to 10 3. We are assuming
that tumors we are modeling have already evolved chromo-
somal instability (CIN) and therefore that inactivation of a
single copy of a tumor suppressor gene leads to a new dri-
ver mutation, as the other copy will be lost soon thereafter
(Nowak et al. 2002, 2004).
Time between cell divisions has been reported to be on
average 4 days in colorectal cancer (Jones et al. 2008a) and
3 days in glioblastoma multiforme (Hoshino and Wilson
1979). In this paper, we will assume the time between cell
divisions is 3 days.
Growth rates of tumors can be estimated from the
reports of the tumor volume doubling time. Average
reported volume doubling times of breast cancer range
between 105 and 270 days (Kusama et al. 1972; Amerlo ¨v
et al. 1992) and between 61 and 269 days for adenocarci-
noma of the lung (Schwartz 1961; Spratt et al. 1963; Weiss
1974). It follows that the average growth coefﬁcient of these
advanced tumors can vary from 0.008 to 0.035, assuming
3 days between cell divisions. Early lesions have smaller
growth rates, and some metastases can grow even faster
(Friberg and Mattson 1997). For this reason, in our paper
we consider growth coefﬁcients of resident cells from 0.002
to 0.04.
At some size during tumor growth, the tumor needs to
develop blood vessels to provide enough oxygen and nutri-
ents required for survival and further growth to the tumor
cells. It has been estimated that the maximum size of a
tumor without blood vessels is 1-2 mm in diameter (Kerbel
2000). This maximum size acts as a carrying capacity in
tumor progression. Based on the prior estimation, this car-
rying capacity is on the order of millions of cells in our
logistic growth model. In our simulations, we will consider
carrying capacities of 104 to 108 cells.
Results
Our ﬁrst result applies to either version of the model. We
ﬁnd that, for reasonably small mutation rate u (and reason-
ably large density limit K in the logistic model), the addi-
tional driver mutation has no effect on the overall survival
probability of the tumor. This is because the mutation gen-
erally occurs when the number of cells in the tumor is
 1/u (or K, in the logistic model when K < 1/u) and there
is no longer a chance for extinction.
Following Bozic et al. (2010), we obtain that for either
version, the tumor survival probability is given by
p ¼ 2s0=ð1 þ s0Þ. This is the probability that a lineage aris-
ing from a single cell will not become extinct. When the
growth coefﬁcient of resident cells is small (s0   1), this
survival probability can be approximated as 2s0.
Exponential growth model
We now focus on the basic model of exponential tumor
growth, assuming small growth coefﬁcients of resident and
mutant cells and a small driver mutation rate (s0   1,
s1   1, and u   s0). Following Bozic et al. (2010), we cal-
culate the expected number of resident cells at time t (mea-
sured in units of cell division time) as
x0ðtÞ¼
1
2s0
ð1 þ s0Þ
t: ð1Þ
We note that this average is conditioned on the survival
of the tumor. The expected time until the appearance of
the ﬁrst mutant cell with a surviving lineage is
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 34–45 37
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1
s0
log
2s0
2
s1u
  
; ð2Þ
assuming a small growth coefﬁcient of resident and mutant
cells and small mutation rate (s0   1, s1   1, and u   s0).
The expected number of mutant cells t′ time steps after the
appearance of the ﬁrst mutant cell with a surviving lineage is
x1ðtÞ¼
1
2s1
ð1 þ s1Þ
t0
: ð3Þ
Although there is stochasticity in the timing of the
appearance of the ﬁrst mutant cell with a surviving lineage,
we can achieve a good approximation to the number of
mutant cells at time t by setting t′ = t τ in eqn (3).
Using the eqn (1) for the average number of resident
cells, we can approximate the time until there are M resi-
dent cells in the tumor as
t0
M ¼
logð2s0MÞ
s0
: ð4Þ
Respectively, the time t1
M until there are M mutant cells
in the tumor is:
t1
M ¼ s þ
logð2s1MÞ
s1
: ð5Þ
We note that in eqns (1), (4), and (5), time is measured
in numbers of cell divisions and needs to be multiplied by
average time between cell divisions to represent real time.
Since resident and mutant cells grow exponentially with
different growth rates, we expect that tumors will most
often be dominated by one cell type: for short times,
tumors will consist mostly of resident cells; for long
times, they will consist mostly of mutant cells (Fig. 3).
Thus, we approximate the expected detection time of the
tumor as
tM ¼ minðt0
M;t1
MÞ: ð6Þ
Figure 4A shows the agreement between formula (6)
and computer simulations.
If t0
M \t1
M, we expect that the tumor will consist mostly
of resident cells (Fig. 3). Consequently, the additional dri-
ver mutation does not have a signiﬁcant effect on detection
time. This observation suggests the following approximate
rule: the additional driver mutation has an effect if
alogðMuÞþð a   1Þloga[ logð2Ms0Þ: ð7Þ
Here, a denotes the ratio s1=s0. From the above inequal-
ity, we see that larger a and u increase the likelihood of a
mutant-dominated tumor (at the time of detection), while
larger s0 increases the chance of a resident-dominated
tumor.
In many clinical contexts, it is reasonable to assume that
Mu ≫ 1 (see Discussion). In this case, the above rule can be
simpliﬁed further by rewriting the left-hand side of
inequality (7) and observing that a log (aMu) ≫ log a.
This leads to the following simpliﬁcation of inequality (7):
alogðaMuÞ[ logð2Ms0Þ: ð8Þ
We show the agreement between the rule (8) and simula-
tions in Fig. 5. Using eqn (8) we ﬁnd that, if the driver
mutation rate is u ¼ 10 7, the detection size is M ¼ 109,
and the growth coefﬁcient of resident cells is s0 ¼ 0:004,
then mutant cells need a three times higher growth coefﬁ-
cient than resident cells to affect tumor detection time. For
(A) (B) (C)
Figure 3 Dominating cell types in the tumor at detection time. Cumulative probability distribution of the tumor detection time (i.e., PðXðtÞ MÞ),
as calculated from 107 simulation runs. The blue shaded regions correspond to tumors dominated by resident cells (more than 50% of the tumor cells
at detection time are resident), while the red shaded regions correspond to tumors dominated by mutant cells at detection time (more than 50% of
the tumor cells at detection time are mutants). The tumor composition at detection time can be estimated by the ratio t0
M=t1
M. Parameter values: driver
mutation rate u ¼ 10 7, detection size M ¼ 109 cells, average cell division time is 3 days.
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 34–45 38
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before, mutant cells need a 1.6 times higher growth coefﬁ-
cient than resident cells to affect detection time.
Logistic growth model
We now consider the situation where the growth of resident
cells is density limited. To analyze the expected appearance
time τ of the ﬁrst mutant cell with surviving lineage, we
need to distinguish between two cases: (i) the ﬁrst surviving
mutant is generated before the resident cells reach their car-
rying capacity and (ii) the ﬁrst surviving mutant is gener-
ated when the resident cells are at their carrying capacity.
In Appendix A, we show that the ﬁrst case is expected to
occur for Ku [ s0=s1 (or, equivalently, aKu > 1) and the
second case for Ku\s0=s1 (aKu < 1). We note that for
s0 ¼ s1, these two cases are divided by Ku = 1.
The expected appearance time τ of the ﬁrst mutant cell
with a surviving lineage is calculated in Appendix A as
s  
1
s0 log
2s0
au
  
if aKu [ 1
1
s0 logð2s0KÞþ 1
aKu   1
  
otherwise:
(
ð9Þ
If the detection size M is smaller than the carrying capac-
ity of resident cells, K, then the model behaves similarly to
the exponential growth model. Thus, we restrict our atten-
tion to the case K < M. In that case, the expected detection
time of the tumor is
tM ¼ s þ
logð2s1 MÞ
s1
; ð10Þ
where τ is given by eqn (9). We show the excellent agree-
ment between eqn (10) and simulation results in Fig. 4B.
Using formula (10), we ﬁnd that, for carrying capacity
K ¼ 106, driver mutation rate u ¼ 10 5, growth coefﬁ-
cients of resident and mutant cells s0 ¼ s1 ¼ 0:004, and
detection size M ¼ 109 cells, the average tumor detection
(A) (B)
Figure 4 Comparison of analytical and simulation results for the expected time of tumor detection. Markers (circle, triangle, square) indicate simula-
tion results while curves represent analytic predictions. In the exponential model (A), we observe that, for typical mutation rates, the additional driver
needs to have a three times higher growth coefﬁcient in order for the mutant type to accelerate tumor progression prior to detection. In the logistic
growth model (B), the additional driver mutation is neutral (s1 ¼ s0). We see that small carrying capacities (with aKu < 1) signiﬁcantly slow tumor
progression, while large carrying capacities (aKu > 1) have little effect. Simulation results are averages over 107 runs. Parameter values: detection size
M ¼ 109 cells, driver mutation rate u ¼ 10 7, average cell division time is 3 days.
(A) (B)
Figure 5 Effect of the additional driver mutation on tumor detection time. The markers represent simulation results for the exponential growth
model, with mutant growth coefﬁcient equal to (green crosses), twice (blue circles), and four times (red triangles) the resident growth coefﬁcient.
The dashed lines correspond to the threshold (8) indicating when the additional driver mutation accelerates tumor progression. Simulation results are
averages over 107 runs. Parameter values: detection size M ¼ 109 cells, average cell division time is 3 days.
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 34–45 39
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all other parameters are the same as before, the average
tumor detection time is  70 years. In any one patient,
multiple such lesions could be seeded, but only a small
fraction of them would reach detectable size in the lifetime
of the patient (see Table 3). Additional results are provided
in Appendix S.1.
Discussion
Our results describe how additional driver mutations affect
the dynamics of tumor growth in different stages of disease
progression. Early lesions often have a limited growth
potential due to spatial or metabolic constraints and need
additional driver mutations to reach a detectable size. In
Table 1. Probability of tumor detection over time in the exponential growth model.
s0 s1
Probability of detection after
5 years 10 years 20 years 30 years 40 years 50 years
0.002 0.002 0.0 0.0 0.0 0.0 0.0 0.0
0.004 0.0 0.0 0.0 0.0 0.0 0.003
0.008 0.0 0.0 0.0 0.002 0.024 0.226
0.004 0.004 0.0 0.0 0.0 0.026 0.973 1.0
0.008 0.0 0.0 0.001 0.436 0.974 1.0
0.016 0.0 0.0 0.01 0.598 0.995 1.0
0.01 0.01 0.0 0.0 0.999 1.0 1.0 1.0
0.02 0.0 0.002 1.0 1.0 1.0 1.0
0.04 0.0 0.032 1.0 1.0 1.0 1.0
0.02 0.02 0.0 0.999 1.0 1.0 1.0 1.0
0.04 0.0 0.999 1.0 1.0 1.0 1.0
0.08 0.012 1.0 1.0 1.0 1.0 1.0
0.04 0.04 0.997 1.0 1.0 1.0 1.0 1.0
0.08 0.997 1.0 1.0 1.0 1.0 1.0
0.16 0.999 1.0 1.0 1.0 1.0 1.0
The birth probability of the resident and mutant cells is given by 1
2ð1 þ s0Þ and 1
2ð1 þ s1Þ, respectively. A higher growth coefﬁcient of the mutant, s1,
can accelerate tumor progression. When s0 ¼ s1, the detection time is independent of the mutation rate. The simulation results are averages over
107 runs. Parameter values: detection size M ¼ 109 cells, driver mutation rate u ¼ 10 7, average cell division time is 3 days. (The value 0.0 corre-
sponds to a probability below 10 3.)
Table 2. Probability of tumor detection over time in the logistic growth model.
s0 K
Probability of detection after
10 years 20 years 30 years 40 years 50 years 60 years
0.002 104 0.0 0.0 0.0 0.0 0.0 0.0
106 0.0 0.0 0.0 0.0 0.0 0.0
108 0.0 0.0 0.0 0.0 0.0 0.0
0.004 104 0.0 0.0 0.0 0.030 0.27 0.538
106 0.0 0.0 0.0 0.062 0.944 1.0
108 0.0 0.0 0.0 0.123 0.98 1.0
0.01 104 0.0 0.152 0.729 0.918 0.975 0.992
106 0.0 0.706 1.0 1.0 1.0 1.0
108 0.0 0.877 1.0 1.0 1.0 1.0
0.02 104 0.076 0.904 0.991 0.999 1.0 1.0
106 0.301 1.0 1.0 1.0 1.0 1.0
108 0.566 1.0 1.0 1.0 1.0 1.0
0.04 104 0.883 0.999 1.0 1.0 1.0 1.0
106 1.0 1.0 1.0 1.0 1.0 1.0
108 1.0 1.0 1.0 1.0 1.0 1.0
The resident cells have a birth probability of 1
2ð1 þ s0ð1   X=KÞÞ, which depends on the current tumor size X. The birth probability of the mutant cells
is constant 1
2ð1 þ s1Þ. If the carrying capacity K is low but the mutation rate u is high (more precisely, if Ku [ s0=s1), tumor progression is not
decelerated. The simulation results are averages over 107 runs. Parameter values: growth coefﬁcient s1 ¼ s0, driver mutation rate u ¼ 10 5 (see
Table 3 for u ¼ 10 7), detection size M ¼ 109 cells, average cell division time is 3 days. (The value 0.0 corresponds to a probability below 10 3.)
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 34–45 40
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which does not leave enough time for a new driver muta-
tion to appear and reach signiﬁcant abundance to affect
detection time. In addition, metastases often have shorter
doubling times (and thus larger s0) compared with early
lesions (Welin et al. 1963; Tanaka et al. 2004). Thus, addi-
tional drivers can more signiﬁcantly increase the growth
rate (leading to a higher s1=s0 ratio) of an early lesion com-
pared to a metastasis. An additional driver would have to
increase an already large growth rate of a metastasis drasti-
cally to have an effect on detection time (Table 1). These
results explain why metastases may not contain additional
driver mutations compared to primary tumors (Jones et al.
2008a).
In the case that resident tumor cells are subject to a den-
sity limitation, the effect of this density limitation on tumor
dynamics depends strongly on the product of the carrying
capacity K and the driver mutation rate u. (More speciﬁ-
cally, the dynamics depend on the product aKu, but
a ¼ s1=s0 can be expected to be in the range 1–10, whereas
K and u may be much more variable across different clinical
contexts.) If Ku [ s0=s1, the ﬁrst surviving mutant appears
before the tumor growth is decelerated by the carrying
capacityfortheresidentcells(seeeqn(9)andTable 2);thus,
the density constraint has little or no effect on the dynamics.
However, if Ku\s0=s1, the ﬁrst surviving mutant appears
only after the tumor has reached the carrying capacity. In
this case, the carrying capacity can tremendously decelerate
tumor progression (Table 3). For example, if
s0 ¼ s1 ¼ 0:01 and u ¼ 10 7, then for K ¼ 107 the
expected detection time, t109, is 23.9 years but for K ¼ 105,
t109 ¼ 101:5 years. From these two examples, we see that in
many cases, carrying capacities are either overcome almost
as soon as they are reached (if Ku [ s0=s1) or delay tumors
to such an extent that they never reach detectable size (if
Ku   s0=s1). Only in the intermediate case that Ku has the
same order of magnitude as s0=s1 (which itself is likely in the
range 0.1–1), would the delay in cancer progression due to
carrying capacity be observable.
The product Ku—and more generally, products of the
form (number of cells) 9 (mutation rate)—also plays an
important role in quantifying the likelihood of treatment
failure due to acquired resistance (Goldie and Coldman
1979; Coldman and Goldie 1983, 1986; Komarova and Wo-
darz 2005; Iwasa et al. 2006; Durrett and Moseley 2010;
Foo and Michor 2010; Leder et al. 2011; Read et al. 2011;
Bozic et al. 2012). Intuitively, this product represents the
number of mutations generated per cell division time in a
population of cells. If this product is much greater than
one, then mutations of interest (e.g., driver mutations,
resistance mutations) are ubiquitous; if the product is
much less than one, then they are rare. This product can
therefore be used as a rule of thumb to determine the dan-
ger posed by a certain variety of mutation. We caution,
however, that other parameters, such as division rates,
death rates, and time spent at a certain population size (Bo-
zic et al. 2012), also play important roles in determining
the likelihood of clinically relevant mutations.
Table 3. Probability of tumor detection over time in the logistic growth model.
s0 K
Probability of detection after
10 years 20 years 30 years 40 years 50 years 60 years
0.002 104 0.0 0.0 0.0 0.0 0.0 0.0
106 0.0 0.0 0.0 0.0 0.0 0.0
108 0.0 0.0 0.0 0.0 0.0 0.0
0.004 104 0.0 0.0 0.0 0.0 0.003 0.008
106 0.0 0.0 0.0 0.0 0.036 0.286
108 0.0 0.0 0.0 0.0 0.087 0.957
0.01 104 0.0 0.002 0.013 0.025 0.036 0.048
106 0.0 0.008 0.575 0.873 0.962 0.989
108 0.0 0.01 1.0 1.0 1.0 1.0
0.02 104 0.001 0.023 0.046 0.069 0.091 0.112
106 0.002 0.849 0.986 0.999 1.0 1.0
108 0.002 1.0 1.0 1.0 1.0 1.0
0.04 104 0.021 0.065 0.108 0.149 0.188 0.225
106 0.817 0.998 1.0 1.0 1.0 1.0
108 1.0 1.0 1.0 1.0 1.0 1.0
The resident cells have a birth probability of 1
2ð1 þ s0ð1   X=KÞÞ, which depends on the current tumor size X. The birth probability of the mutant cells
is constant 1
2ð1 þ s1Þ. If the carrying capacity K and/or mutation rate u is small (more precisely, if Ku\s0=s1), the tumor progression is signiﬁcantly
slowed by the density limitation. The simulation results are averages over 107 runs. Parameter values: growth coefﬁcient s1 ¼ s0, driver mutation rate
u ¼ 10 7 (see Table 2 for u ¼ 10 5), detection size M ¼ 109 cells, average cell division time is 3 days. (The value 0.0 corresponds to a probability
below 10 3.)
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Reiter et al. Effects of driver mutations on tumor progressionIn this work, we derived conditions that help determine
whether the additional driver mutation will signiﬁcantly
accelerate tumor progression. In reality, most solid tumors
need several driver mutations to reach advanced carcinoma
and metastatic stage that are most detrimental to the
patient. When comparing our results to previous modeling
work on the accumulation of multiple driver mutations in
tumors (Beerenwinkel et al. 2007; Beckman 2009; Bozic
et al. 2010), one should keep in mind that the times to
detection of a lesion might be shorter than reported here if
the cells could quickly receive several drivers.
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Appendix A – Mutant appearance time
To analyze the expected appearance time τ of the ﬁrst
surviving mutant cell, we use the fact that until very close
to their carrying capacity, resident cells will on average
grow exponentially. Thus, we can approximate their
growth by two phases: exponential and steady state. In
this approximation, the average time to reach steady state
is given by
tK ¼
logð2s0KÞ
s0
: ðA:1Þ
If the ﬁrst surviving mutant is generated during the
exponential phase, then its average time of appearance τ is
given by equation (2), and we must have s\tK. Compar-
ing (2) and (A.1), we see that s\tK is equivalent to
Ku [ s0=s1. We conclude that (i) if Ku [ s0=s1 the ﬁrst
surviving mutant is generated before resident cells reach
the carrying capacity and (ii) if Ku\s0=s1 the ﬁrst surviv-
ing mutant is generated after resident cells have reached the
carrying capacity.
In the second case, we approximate the time until the
appearance of the ﬁrst surviving mutant, τ, by the time
when the total expected number of surviving mutants pro-
duced reaches 1. This leads to the equation
1 ¼
X tK
t¼1
x0ðtÞ
1
2
ð1 þ s0Þu2s1 þ
X s
t¼tK
K
1
2
u2s1: ðA:2Þ
Using the formula for a geometric series, we obtain
X tK
t¼1
x0ðtÞ¼
X tK
t¼1
ð1 þ s0Þ
t ¼
ðK   1Þð1 þ s0Þ
s0
:
Substituting this in (A.2) and solving for τ yields
s ¼
1
s0
logð2s0KÞþ
1
Kus1=s0
 ð 1 þ s0Þ
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K
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Figure A.1 Mutant appearance time in the logistic growth model.
Comparison of analytical and simulation results for the expected
appearance time of the ﬁrst surviving mutant in the logistic growth
model. Circles, triangles, squares, and diamonds correspond to the
average results of the simulation, and lines correspond to the analytical
result, eqn (9). Simulation results are averages over 107 runs. Parameter
values: detection size M ¼ 109 cells, driver mutation rate u ¼ 10 7,
average cell division time is 3 days.
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